EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation

Byron Brook, Morgan Goetz, Valerie Duval, Romain Micol, David J Dowling

Trends in Immunology · 2025

DOI: 10.1016/j.it.2025.03.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Immunology, 2025. Verfasst von Byron Brook und 4 weiteren Autor:innen. Beteiligte Einrichtung: Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: MicroRNAs, SARS-CoV-2, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Merck Sharp and Dohme United Kingdom, NIH NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of ionizable mRNA-lipid nanoparticle (mRNA-LNP) nucleic acid carriers facilitated the clinical translation of the Coronavirus 2019 (COVID-19) mRNA vaccines BNT162b2 and mRNA-1273. Here, we discuss insights into rational improvements to mRNA vaccines, focusing on LNP modifications for mRNA-LNP biodistribution control, miRNA-based biodistribution control of encoded transcripts, and precision adjuvantation strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsSARS-CoV-2COVID-19COVID-19 VaccinesmRNA VaccinesRNA, MessengerHumansAnimalsNanoparticlesTissue DistributionAdjuvants, ImmunologicBNT162 Vaccine2019-nCoV Vaccine mRNA-1273LipidsLiposomes

Stichwörter der Autor:innen

adjuvantsbiodistributionmRNA vaccinesmicroRNA

Substanzen

MicroRNAsCOVID-19 VaccinesmRNA VaccinesAdjuvants, ImmunologicBNT162 VaccineLipid NanoparticlesRNA, Messenger2019-nCoV Vaccine mRNA-1273LipidsLiposomes

Autor:innen und Institutionen

  • Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Combined Therapeutics Incorporated, Boston, MA 02135, USA.
  • Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: david.dowling@childrens.harvard.edu.

Förderung

  • NIAID NIH HHS
  • Merck Sharp and Dohme United Kingdom
  • NIH NIAID
  • Merck

Zitieren

APA

Brook, B., Goetz, M., Duval, V., Micol, R., & Dowling, D. J. (2025). mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation. Trends in Immunology. https://doi.org/10.1016/j.it.2025.03.004

Vancouver

Brook B, Goetz M, Duval V, Micol R, Dowling DJ. mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation. Trends in Immunology. 2025. doi:10.1016/j.it.2025.03.004

BibTeX
@article{Brook2025,
  author = {Brook, Byron and Goetz, Morgan and Duval, Valerie and Micol, Romain and Dowling, David J},
  title = {mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation},
  journal = {Trends in Immunology},
  year = {2025},
  doi = {10.1016/j.it.2025.03.004}
}
Kostenlos starten →